In a new job - July 16, 2021
AstraZeneca appoints new EVP in Oncology R&D
AstraZeneca has appointed Susan Galbraith to lead Oncology Research & Development from initial discovery through late-stage development. Her appointment follows the passing of José Baselga earlier this year. She will join the company’s Senior Executive Team and report to Chief Executive Officer, Pascal Soriot. “I am honoured to take on this position as we continue […]
COVID-19 - July 15, 2021
New findings about Vaxzevria’s induced immunity
A sub-analysis from the Oxford-led COV001 and COV002 trials with Vaxzevria induced strong immune responses following either a prolonged second dose interval of up to 45 weeks or following a third boosting dose. The results, published by the University of Oxford on the pre-print server of The Lancet, demonstrated that antibody levels remain elevated from baseline for […]
Clinical Trials - July 5, 2021
New results from AstraZeneca’s MEDLEY trial
The MEDLEY Phase II/III trial evaluated the safety and tolerability of nirsevimab compared to Synagis (palivizumab) when given to infants at high risk of respiratory syncytial virus (RSV) entering their first RSV season. The trial assessed the safety of nirsevimab in infants with chronic lung disease (CLD), congenital heart disease (CHD) and/or prematurity. Occurrence of […]
Pharma Business - June 30, 2021
AstraZeneca’s Lynparza approved in China
AstraZeneca and MSD’s Lynparza has been granted conditional approval in China to treat adult patients with germline or somatic BRCA-mutated metastatic castration-resistant prostate cancer who have progressed following treatment that included a new hormonal agent. The approval by China’s National Medical Products Administration was based on a subgroup analysis of the PROfound Phase III trial, […]
COVID-19 - June 16, 2021
Update on AstraZeneca’s STORM CHASER trial
The company has announced results from a trial assessing the safety and efficacy of AZD7442, a long-acting antibody (LAAB) combination, for the prevention of symptomatic COVID-19 in participants recently exposed to the SARS-CoV-2 virus. The trial did not meet the primary endpoint of post-exposure prevention of symptomatic COVID-19 with AZD7442 compared to placebo, writes the […]
Clinical Trials - June 7, 2021
New results from AstraZeneca’s OlympiA trial
Results from the Phase III trial showed that AstraZeneca and MSD’s Lynparza demonstrated a statistically significant and clinically meaningful improvement in invasive disease-free survival versus placebo in the adjuvant treatment of patients with germline BRCA-mutated high-risk human epidermal growth factor receptor 2 (HER2)-negative early breast cancer. “This is the first time that any medicine targeting […]
